Trials & Filings

Oxford BioTherapeutics, Boehringer’s ADC for Lung Cancer Gets Fast Tracked

BI 764532 demonstrates a clinically acceptable safety profile and early efficacy late-stage small cell lung cancer and neuroendocrine cancer.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, was granted Fast Track designation from the FDA for BI 764532 for the treatment of extensive stage small cell lung cancer (ES-SCLC) whose disease has progressed following treatment, and of advanced or metastatic extrapulmonary neuroendocrine carcinomas (epNEC) whose disease has progressed following treatment including platinum-based chemotherapy. ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters